Hansa Biopharma AB (publ) EBIT

The latest EBIT for HNSBF is $-580M as of June 2026. That compares with $-460M in the prior-year period — down 27.1% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Hansa Biopharma AB (publ)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, HNSBF's EBIT moved from $-460M to $-580M — a 27.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Hansa Biopharma AB (publ)'s operating scale or balance-sheet position.

Against Healthcare companies, HNSBF currently prints $-580M for EBIT, while the sector average sits near $99B. That is roughly 100.6% below the sector mean. Large gaps often invite a closer look at Hansa Biopharma AB (publ)'s growth, margins, and balance sheet.

A EBIT figure of $-580M for HNSBF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting HNSBF's EBIT ($-580M), review year-over-year change from $-460M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.